Participants: ≥18 years, inactive non-infectious intermediate, posterior or panuveitic uveitis. At least one disease flare within 18 months of screening visit. On oral prednisone 10-35mg/day to maintain inactivity.
Intervention:
Group 1: Placebo
Group 2: Adalimumab (80mg loading dose then 40mg every 2 weeks)
Both groups were on Prednisone 10-35mg/day at baseline and were tapered off to 0mg by week 19.
Source Archive